REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD [Yahoo! Finance]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Yahoo! Finance
Biopharma executive with more than 35 years of leadership across C-suite and board roles Lausanne, Switzerland and Copenhagen, Denmark, March 19, 2026 - ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women's health, today announced the appointment of Mark Altmeyer as Chairman of the Board of Directors. Mark Altmeyer brings more than 35 years of experience as a biopharma executive and board leader across large pharma and high-growth biotech companies focusing on multiple therapeutic areas. He has deep expertise in commercialization strategy, M&A and international expansion, with a strong track record of driving growth and enterprise value in both public and private company settings. Altmeyer is recognized for fostering high-performing teams, aligning investors and management around clear value-creation priorities. Mark Altmeyer “Mark is distinguished by a rare blend of board-level leadership a
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences (ROIV) is now covered by Sanford C. Bernstein. They set an "outperform" rating and a $35.00 price target on the stock.MarketBeat
- A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences (ROIV) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance]Yahoo! Finance
- Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang [Yahoo! Finance Canada]Yahoo! Finance Canada
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 3/23/26 - Form 8-K/A
- 3/19/26 - Form 4
- 3/18/26 - Form 4
- ROIV's page on the SEC website